Qiagen announced an agreement to be taken private in an all-cash transaction led by EQT XI, valuing the company at about $12.1 billion including net debt and representing a 40.3% premium to the prior XETRA close. The deal structure includes indirect participation from Luxinva (Abu Dhabi Investment Authority) and CPP Investment Board Europe. The company’s board backed the move to private ownership, citing operational flexibility and the ability to invest behind strategic opportunities. The transaction would keep Qiagen operating under its current name and brand until closing, and targets an 80% vote threshold for post-closing measures. While not a direct therapeutic asset acquisition, Qiagen’s portfolio and technology stack are central to workflows across biotech manufacturing and diagnostics, so ownership changes can affect the pace of platform investment and customer roadmap planning.